company background image
GNFT

Genfit ENXTPA:GNFT Stock Report

Last Price

€3.81

Market Cap

€189.2m

7D

0.4%

1Y

5.7%

Updated

30 Jan, 2023

Data

Company Financials +

GNFT Stock Overview

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.

GNFT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance4/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Genfit S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genfit
Historical stock prices
Current Share Price€3.81
52 Week High€4.77
52 Week Low€2.80
Beta1.03
1 Month Change-3.98%
3 Month Change-4.99%
1 Year Change5.72%
3 Year Change-75.58%
5 Year Change-85.18%
Change since IPO-70.60%

Recent News & Updates

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Dec 28
We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30
New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Recent updates

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Dec 28
We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30
New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29
Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14
Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Is Genfit (EPA:GNFT) A Risky Investment?

Nov 28
Is Genfit (EPA:GNFT) A Risky Investment?

Shareholder Returns

GNFTFR BiotechsFR Market
7D0.4%-1.7%1.4%
1Y5.7%-41.0%2.8%

Return vs Industry: GNFT exceeded the French Biotechs industry which returned -41% over the past year.

Return vs Market: GNFT exceeded the French Market which returned 2.8% over the past year.

Price Volatility

Is GNFT's price volatile compared to industry and market?
GNFT volatility
GNFT Average Weekly Movement4.0%
Biotechs Industry Average Movement7.1%
Market Average Movement4.4%
10% most volatile stocks in FR Market9.8%
10% least volatile stocks in FR Market2.4%

Stable Share Price: GNFT is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: GNFT's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999134M. Prigenthttps://www.genfit.com

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company’s products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure.

Genfit S.A. Fundamentals Summary

How do Genfit's earnings and revenue compare to its market cap?
GNFT fundamental statistics
Market Cap€189.19m
Earnings (TTM)€47.80m
Revenue (TTM)€94.24m

4.0x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GNFT income statement (TTM)
Revenue€94.24m
Cost of Revenue€0
Gross Profit€94.24m
Other Expenses€46.44m
Earnings€47.80m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Apr 13, 2023

Earnings per share (EPS)0.96
Gross Margin100.00%
Net Profit Margin50.72%
Debt/Equity Ratio62.2%

How did GNFT perform over the long term?

See historical performance and comparison